Citigroup’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Citigroup’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-231	Closed	-$20.1K	–	5935
2022 Q4	$20.1K	Buy	231 +224	+3,200%	+$40.6K	﹤0.01%	4591
2022 Q3	$5K	Buy	+7	New	+$2.24K	﹤0.01%	5249
2022 Q2	–	Hold	0	–	–	–	6756
2021 Q2	–	Hold	0	–	-$3K	–	6457
2021 Q1	–	Sell	-1	Closed	-$6.87K	–	6018
2020 Q4	$7K	Buy	+1	New	+$5.24K	﹤0.01%	7057
2020 Q3	–	Sell	-1	Closed	-$12.2K	–	7246
2020 Q2	$9K	Hold	1	–	–	﹤0.01%	7110
2020 Q1	$10K	Buy	+1	New	+$10K	﹤0.01%	7057

Other funds holding ATXI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

IWP

Icon Wealth Partners Houston, Texas $880M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's ATXI Position: Q1 2023 in Review

Citigroup sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2023, closing a stake of 231 shares — an estimated $20.1K sold.

Citigroup first reported a position in ATXI in Q1 2020 and held it in 5 quarters. The position peaked at $20.1K in Q4 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2023.

Citigroup reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citigroup sold 231 Avenue Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $20.1K.
Citigroup first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Citigroup's Avenue Therapeutics, Inc. Common Stock position peaked at $20.1K in Q4 2022.
13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.